dupilumab
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
22
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Moderate-to-severe Atopic Dermatitis
Conditions
Moderate-to-severe Atopic Dermatitis
Trial Timeline
Jan 27, 2022 → Mar 10, 2023
NCT ID
NCT05203380About dupilumab
dupilumab is a pre-clinical stage product being developed by Sanofi for Moderate-to-severe Atopic Dermatitis. The current trial status is completed. This product is registered under clinical trial identifier NCT05203380. Target conditions include Moderate-to-severe Atopic Dermatitis.
Hype Score Breakdown
Clinical
5
Activity
2
Company
9
Novelty
2
Community
1
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05906706 | Pre-clinical | Completed |
| NCT07316114 | Pre-clinical | Recruiting |
| NCT07467564 | Pre-clinical | Recruiting |
| NCT07187089 | Approved | Withdrawn |
| NCT07112378 | Phase 3 | Recruiting |
| NCT07052396 | Pre-clinical | Recruiting |
| NCT07276425 | Pre-clinical | Recruiting |
| NCT06695897 | Pre-clinical | Recruiting |
| NCT06693531 | Pre-clinical | Recruiting |
| NCT06415175 | Pre-clinical | Active |
| NCT06556264 | Approved | Recruiting |
| NCT06352073 | Approved | Recruiting |
| NCT06293053 | Phase 3 | Recruiting |
| NCT05983068 | Approved | Active |
| NCT06234761 | Pre-clinical | Recruiting |
| NCT05991323 | Pre-clinical | Active |
| NCT06192563 | Pre-clinical | Recruiting |
| NCT06169527 | Pre-clinical | Active |
| NCT06393946 | Pre-clinical | Active |
| NCT05831176 | Phase 2 | Active |
Competing Products
13 competing products in Moderate-to-severe Atopic Dermatitis